Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
Background: Busulfan pharmacokinetics exhibit large inter-subject variability. Our objective was to evaluate the influence of glutathione S-transferase A1 (<i>GSTA1</i>) gene variants on busulfan oral clearance (CLo) in a population of patients undergoing hematopoietic stem cell transpla...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/9/440 |
id |
doaj-d6d3d201f719408995e2c4aebb62ef4b |
---|---|
record_format |
Article |
spelling |
doaj-d6d3d201f719408995e2c4aebb62ef4b2020-11-24T20:45:12ZengMDPI AGPharmaceutics1999-49232019-09-0111944010.3390/pharmaceutics11090440pharmaceutics11090440Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell TransplantationVeronique Michaud0My Tran1Benoit Pronovost2Philippe Bouchard3Sarah Bilodeau4Karine Alain5Barbara Vadnais6Martin Franco7François Bélanger8Jacques Turgeon9Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaCollege of Pharmacy, Lake Nona Campus, University of Florida, Orlando, FL 32827, USAFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaCRCHUM, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC H2X 0A9, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaBackground: Busulfan pharmacokinetics exhibit large inter-subject variability. Our objective was to evaluate the influence of glutathione S-transferase A1 (<i>GSTA1</i>) gene variants on busulfan oral clearance (CLo) in a population of patients undergoing hematopoietic stem cell transplantation. Methods: This is a quasi-experimental retrospective study in adult patients (<i>n</i> = 87 included in the final analyses) receiving oral busulfan. Pharmacokinetics data (area under the plasma concentration-time curve (AUC) determined from 10 blood samples) were retrieved from patients’ files and <i>GSTA1 *A</i> and <i>*B</i> allele polymorphisms determined from banked DNA samples. Three different limited sampling methods (LSM) using four blood samples were also compared. Results: Carriers of <i>GSTA1*B</i> exhibited lower busulfan CLo than patients with an <i>*A/*A</i> genotype (<i>p</i> < 0.002): Busulfan CLo was 166 ± 31, 187 ± 37 vs. 207 ± 47 mL/min for <i>GSTA1*B/*B,</i> <i>*A/*B</i> and <i>*A/*A</i> genotypes, respectively. Similar results were obtained with the tested LSMs. Using the standard AUC method, distribution of patients above the therapeutic range after the first dose was 29% for <i>GSTA1*A/*A</i>, 50% for <i>*A/*B,</i> and 65% for <i>*B/*B</i>. The LSMs correctly identified ≥91% of patients with an AUC above the therapeutic range. The misclassified patients had a mean difference less than 5% in their AUCs. Conclusion: Patients carrying <i>GSTA1</i> loss of function <i>*B</i> allele were at increased risk of overdosing on their initial busulfan oral dose. Genetic polymorphisms associated with <i>GSTA1</i> explain a significant part of busulfan CLo variability which could be captured by LSM strategies.https://www.mdpi.com/1999-4923/11/9/440busulfanglutathione S-transferasegenetic polymorphismlimited sampling strategypharmacokinetics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Veronique Michaud My Tran Benoit Pronovost Philippe Bouchard Sarah Bilodeau Karine Alain Barbara Vadnais Martin Franco François Bélanger Jacques Turgeon |
spellingShingle |
Veronique Michaud My Tran Benoit Pronovost Philippe Bouchard Sarah Bilodeau Karine Alain Barbara Vadnais Martin Franco François Bélanger Jacques Turgeon Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation Pharmaceutics busulfan glutathione S-transferase genetic polymorphism limited sampling strategy pharmacokinetics |
author_facet |
Veronique Michaud My Tran Benoit Pronovost Philippe Bouchard Sarah Bilodeau Karine Alain Barbara Vadnais Martin Franco François Bélanger Jacques Turgeon |
author_sort |
Veronique Michaud |
title |
Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation |
title_short |
Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation |
title_full |
Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation |
title_fullStr |
Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation |
title_full_unstemmed |
Impact of <i>GSTA1</i> Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation |
title_sort |
impact of <i>gsta1</i> polymorphisms on busulfan oral clearance in adult patients undergoing hematopoietic stem cell transplantation |
publisher |
MDPI AG |
series |
Pharmaceutics |
issn |
1999-4923 |
publishDate |
2019-09-01 |
description |
Background: Busulfan pharmacokinetics exhibit large inter-subject variability. Our objective was to evaluate the influence of glutathione S-transferase A1 (<i>GSTA1</i>) gene variants on busulfan oral clearance (CLo) in a population of patients undergoing hematopoietic stem cell transplantation. Methods: This is a quasi-experimental retrospective study in adult patients (<i>n</i> = 87 included in the final analyses) receiving oral busulfan. Pharmacokinetics data (area under the plasma concentration-time curve (AUC) determined from 10 blood samples) were retrieved from patients’ files and <i>GSTA1 *A</i> and <i>*B</i> allele polymorphisms determined from banked DNA samples. Three different limited sampling methods (LSM) using four blood samples were also compared. Results: Carriers of <i>GSTA1*B</i> exhibited lower busulfan CLo than patients with an <i>*A/*A</i> genotype (<i>p</i> < 0.002): Busulfan CLo was 166 ± 31, 187 ± 37 vs. 207 ± 47 mL/min for <i>GSTA1*B/*B,</i> <i>*A/*B</i> and <i>*A/*A</i> genotypes, respectively. Similar results were obtained with the tested LSMs. Using the standard AUC method, distribution of patients above the therapeutic range after the first dose was 29% for <i>GSTA1*A/*A</i>, 50% for <i>*A/*B,</i> and 65% for <i>*B/*B</i>. The LSMs correctly identified ≥91% of patients with an AUC above the therapeutic range. The misclassified patients had a mean difference less than 5% in their AUCs. Conclusion: Patients carrying <i>GSTA1</i> loss of function <i>*B</i> allele were at increased risk of overdosing on their initial busulfan oral dose. Genetic polymorphisms associated with <i>GSTA1</i> explain a significant part of busulfan CLo variability which could be captured by LSM strategies. |
topic |
busulfan glutathione S-transferase genetic polymorphism limited sampling strategy pharmacokinetics |
url |
https://www.mdpi.com/1999-4923/11/9/440 |
work_keys_str_mv |
AT veroniquemichaud impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT mytran impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT benoitpronovost impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT philippebouchard impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT sarahbilodeau impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT karinealain impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT barbaravadnais impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT martinfranco impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT francoisbelanger impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation AT jacquesturgeon impactofigsta1ipolymorphismsonbusulfanoralclearanceinadultpatientsundergoinghematopoieticstemcelltransplantation |
_version_ |
1716815140132749312 |